Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05667597Not ApplicableActive Not Recruiting

Sars-COV-2 (COVID-19) Immunity in immunoCOmpromised Populations

Role: collaborator

NCT05960084Unknown

Impact of Reducing Colistin Use on Colistin Resistance in Humans and Poultry in Indonesia

Role: collaborator

NCT05555303Phase 2Recruiting

Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis

Role: collaborator

NCT01832571Not ApplicableWithdrawn

SCOPE: Strategies to Combine PrEP With Prevention Efforts

Role: collaborator

All 4 trials loaded